A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
A widespread frost across the UK as temperatures fall below freezing under clear skies.
After a vote tainted by reports of ballot-box stuffing and forced voting, Putin said Russia was ready to 'cooperate' with Britain.
Largely dry elsewhere tonight with a widespread frost and icy stretches